# Eloralintide + GLP-1 / Tirzepatide: The Amylin Add-On Stack Explained
> Note: PeptIQ is not a medical provider. Combining investigational amylin agonists with incretin therapies belongs in clinical trials or clinician-supervised care — not unsupervised research-peptide stacking. Educational content only.
Your top-performing stack articles (SS-31 + MOTS-c, BPC + TB-500, 5-Amino-1MQ + GLP-1) work because searchers want complementary mechanisms. Eloralintide fits that pattern on the metabolic side: amylin satiety on top of GLP-1 / GIP incretin control.
Why Stacking Amylin With a GLP-1 Makes Mechanistic Sense
| Pathway | What it mainly does for weight | Typical drugs |
|---|---|---|
| GLP-1 (± GIP) | Appetite, gastric emptying, glycemic control | Semaglutide, tirzepatide |
| Amylin | Meal termination, satiety, gastric emptying (distinct receptor) | Cagrilintide, eloralintide |
| Glucagon (in dual/triple agonists) | Energy expenditure / visceral fat biology | Survodutide, retatrutide (as part of multi-agonism) |
GLP-1 escalation alone eventually hits diminishing returns for some people: more nausea, less incremental loss. Amylin add-on is the industry's answer to "same goal, second receptor."
CagriSema already proved the combo thesis in Phase 3. Lilly is testing whether eloralintide can play a similar role alone or beside weekly incretins.
What Lilly Is Actually Studying
Public program signals include:
- Eloralintide monotherapy — Phase 2 obesity trial with 1–9 mg weekly arms; Phase 3 ENLIGHTEN obesity studies.
- Eloralintide ± tirzepatide — Phase 2 work in adults with obesity/overweight and type 2 diabetes evaluating eloralintide alone or with tirzepatide (e.g., NCT06603571 in public communications).
- ENLIGHTEN-6 — Phase 3 study of once-weekly eloralintide in people with persistent obesity while on a stable weekly incretin (with or without type 2 diabetes).
That third design is the cleanest "stack" question in plain English: if you are already on a weekly incretin and still have residual obesity, does adding amylin help?
What This Is Not
- Not a green light to mix gray-market "eloralintide" with compounded tirzepatide
- Not proof that amylin + retatrutide is studied at every dose people want
- Not the same as dissolving two peptides in one syringe because a forum said so
Evidence tier first. Trial product ≠ research vial.
Practical Tracking Template for Dual-Pathway Protocols
If a clinician ever runs an amylin + incretin combination (approved combo product, trial, or supervised care), log separately:
Incretin channel
- Drug, weekly dose, injection day
- Classic GLP-1 symptoms (nausea curve, constipation)
Amylin channel
